GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » EV-to-FCF

Nicox (LTS:0RCQ) EV-to-FCF : -1.52 (As of May. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Nicox EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nicox's Enterprise Value is €32.19 Mil. Nicox's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-21.14 Mil. Therefore, Nicox's EV-to-FCF for today is -1.52.

The historical rank and industry rank for Nicox's EV-to-FCF or its related term are showing as below:

LTS:0RCQ' s EV-to-FCF Range Over the Past 10 Years
Min: -24.21   Med: -6.32   Max: -0.65
Current: -1.52

During the past 13 years, the highest EV-to-FCF of Nicox was -0.65. The lowest was -24.21. And the median was -6.32.

LTS:0RCQ's EV-to-FCF is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs LTS:0RCQ: -1.52

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Nicox's stock price is €0.3795. Nicox's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.415. Therefore, Nicox's PE Ratio for today is At Loss.


Nicox EV-to-FCF Historical Data

The historical data trend for Nicox's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox EV-to-FCF Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.02 -24.57 -4.85 -2.38 -

Nicox Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.85 - -2.38 - -

Competitive Comparison of Nicox's EV-to-FCF

For the Biotechnology subindustry, Nicox's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nicox's EV-to-FCF falls into.



Nicox EV-to-FCF Calculation

Nicox's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=32.190/-21.135
=-1.52

Nicox's current Enterprise Value is €32.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-21.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox  (LTS:0RCQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nicox's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3795/-0.415
=At Loss

Nicox's share price for today is €0.3795.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.415.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nicox EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nicox's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (LTS:0RCQ) Business Description

Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (LTS:0RCQ) Headlines

No Headlines